American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S3-S10 , 16 June 2008

Identifying the Vulnerable Patient with Rupture-Prone Plaque

  • Howard S. Weintraub, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Howard S. Weintraub, MD, Division of Cardiology, Department of Medicine, New York University Medical Center, 530 First Avenue, Suite 9U, New York, New York 10016.

References 

  1. Rosamond R, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  2. National Heart, Lung, and Blood Institute.. What is the heart truth?. http://www.nhlbi.nih.gov/health/hearttruth/whatis/Accessed July 30, 2007
  3. Khot UM, Khot NB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904
  4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421II–30–II-31
  5. Tuczu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705–2710
  6. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease: an investigation of differences in outcome between the sexes according to initial coronary disease prevention. Circulation. 1993;88:2548–2555
  7. May HT, Horne BD, Anderson JL, Muhlestein JB, Renlund DG, Clarke JL, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152:997–1003
  8. American Cancer Society. Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007;4
  9. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al From vulnerable plaque to vulnerable patient (Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) task force report). Am J Cardiol. 2006;98(suppl):2H–15H
  10. Genest J, McNamara JR, Ordovas JM, Jenner JL, Bilberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792–802
  11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  12. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?. J Am Coll Cardiol. 2003;41:1475–1479
  13. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375
  14. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KAA, Julian DG, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161–1170
  15. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  16. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–2529
  17. Zhang P, Zhang L, Carabasi A, Diehl J, Dimuzio PJ, Dimatteo C, et al. Oxidized LDL-induced upregulation of IL-18 in monocytes/macrophages is modulated by lipoprotein-associated phospholipase A2: potential mechanism of inflammatory burden in atherosclerosis. Circulation. 2006;114:II-24;Abstract 258.
  18. Leon AS, Wilmore JH, Ewy GA, Rankinen T, Rao DC, Skinner JS, et al. Endurance exercise training reduces lipoprotein-associated phospholipase A2 (LP-PLA2) in young white adults: the HERITAGE family study. Med Sci Sports Exerc. 2007;39(suppl):S312
  19. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelsstiel CD, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743–745
  20. Shalwitz RA, Maki KC, Doyle RT, Ballantyne CM. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 (Lp-PLA2) during prescription omega-3 therapy (Program and abstracts of the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference). 2007;April 19–21, 2007; Chicago, Illinois. Abstract P383.
  21. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488
  22. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115:2390–2397
  23. Lerman A. Restenosis: another “dysfunction” of the endothelium. Circulation. 2005;111:8–10
  24. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003;107:2805–2809
  25. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  26. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–C18
  27. Jang I-K, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, et al. In Vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation. 2005;111:1551–1555
  28. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J. Clin Invest. 2003;112:1785–1788
  29. McLaughlin TM, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol. 2004;24:E-67
  30. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7:511–517
  31. Persson M, Hedblad B, Nelson J, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–1416

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00684-X

doi: 10.1016/j.amjcard.2008.04.013

American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S3-S10 , 16 June 2008

Article Tools

* Image Usage & Resolution